77823-55-3

Upstream product

• 3337-62-0 3,5-dibromo-4-hydroxybenzoic acid 
• 110-71-4 1,2-dimethoxyethane 

Downstream Products

• 77823-57-5 (3,5-Dibromo-4-hydroxy-phenyl)-(2-methyl-indolizin-3-yl)-methanone 
• 77823-56-4 2-ethyl-3-(3,5-dibromo-4-hydroxy-benzoyl)-indolizine 
• 77823-59-7 2-isopropyl-3-(3,5-dibromo-4-hydroxy-benzoyl)-indolizine 
• 77823-58-6 (3,5-Dibromo-4-hydroxy-phenyl)-(2-propyl-indolizin-3-yl)-methanone 
• 77823-60-0 (2-Butyl-indolizin-3-yl)-(3,5-dibromo-4-hydroxy-phenyl)-methanone 
• 77823-61-1 (3,5-Dibromo-4-hydroxy-phenyl)-(2-phenyl-indolizin-3-yl)-methanone 
• 85257-93-8 Sodium; 2,6-dibromo-4-(2-p-tolyl-indolizine-3-carbonyl)-phenolate 
• 85257-94-9 Sodium; 2,6-dibromo-4-[2-(4-fluoro-phenyl)-indolizine-3-carbonyl]-phenolate 
• 77823-65-5 [2-(4-Chloro-phenyl)-indolizin-3-yl]-(3,5-dibromo-4-hydroxy-phenyl)-methanone 
• 77832-45-2 [2-(4-Bromo-phenyl)-indolizin-3-yl]-(3,5-dibromo-4-hydroxy-phenyl)-methanone 
• 77823-66-6 (3,5-Dibromo-4-hydroxy-phenyl)-[2-(3,4-dichloro-phenyl)-indolizin-3-yl]-methanone 
• 77823-63-3 (3,5-Dibromo-4-hydroxy-phenyl)-[2-(4-methoxy-phenyl)-indolizin-3-yl]-methanone 
• 77832-44-1 [2-(3-Bromo-phenyl)-indolizin-3-yl]-(3,5-dibromo-4-hydroxy-phenyl)-methanone 
• 865624-11-9 methyl (3,5-dibromo-4-hydroxy-benzoylamino)acetate 

Relevant academic research and scientific papers

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR

The invention provides compounds of formula I or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I) wherein R1, R2, n, Y, Y', R3, R4, W and R5 are as defined in the specification.

THYROID RECEPTOR AGONISTS

The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I), wherein R1, R2, n, Y, Y', R3, R4, W and R5 are as defined in the specification.

Research in indolizines series. Influence of substitution in the neighbourhood of ether function in butoprozine series

The authors prepared 2-alkyl or 2-aryl-3-(4-dialkylaminopropoxy-benzoyl)-indolizines with mono- or di-substitution in the ortho positions of the ether function. The substituents may be halogen atoms or methyl or methoxy groups. The 2-alkyl derivatives mon